| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679945 | Alzheimer's & Dementia | 2018 | 7 Pages |
Abstract
Higher levels of AD biomarkers, including among individuals with preclinical AD, lead to earlier driving cessation. Negative functional outcomes of preclinical AD show a nonbenign phase of the disease.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Sarah H. Stout, Ganesh M. Babulal, Chunyu Ma, David B. Carr, Denise M. Head, Elizabeth A. Grant, Monique M. Williams, David M. Holtzman, Anne M. Fagan, John C. Morris, Catherine M. Roe,